David Marks, MBBS, PhD, FRACP, FRCPath, University Hospitals Bristol NHS Trust, Bristol, UK, comments on the role and importance of measurable residual disease (MRD) assessment prior to allogeneic stem cell transplantation (alloSCT) in patients with acute lymphoblastic leukemia (ALL). Prof. Marks explains that MRD assessment is standard practice for all patients and helps guide transplant decisions. In addition, blinatumomab is now used to help patients reach MRD negativity prior to transplant. Patients who are MRD-positive prior to alloSCT should undergo full-intensity transplantation to ensure the best outcomes. This interview took place at the 49th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) held in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

свернуть